A privacy-first tracker for multi-compound injectable protocols. Log shots, manage vials, track consistency, and hit milestones without subscriptions, ads, or data harvesting. Most tracking apps are built for brand-name GLP-1s. MyRONKO is built for stacks: tirzepatide plus NAD+ plus glutathione plus whatever else your protocol calls for.

Yes. The core features are free and stay free. One less subscription to worry about.

We don’t, yet. When monetization happens, it won’t be through ads, data sales, or paywalling the features that matter. The likely path is optional tip-jar support through Ko-fi for users who want to contribute.

Yes. Your injection history, weights, symptoms, and vial inventory go nowhere you haven’t explicitly sent them. No ads, no data sales, no health data shared with third parties. We use PostHog for anonymized feature analytics (which screens in the app get used, not what you log or personal data).

Yes, a free account. Sign in with email, Google, or Apple ID. Accounts let you sync across devices and restore your data if you lose a phone. Authentication handles identity only. It doesn’t unlock analytics on you.

Yes. Full export anytime, in standard formats you can open in a spreadsheet or import elsewhere. No lock-in.

Now why would you wish this upon us?! No, seriously you have the ability to export and should periodically.

Any injectable protocol. Out of the box, the common ones are configured: GLP-1s (tirzepatide, semaglutide, retatrutide), NAD+, glutathione, peptides (BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295), TRT, HCG, HGH and analogs.

No. It’s a tracker and an educational resource. Protocol choices, dosing, and medical decisions are between you and your provider. Nothing here replaces medical care.

The app is live and usable, but still in active development. Features may change, bugs may surface, and occasional rough edges are part of the deal. Beta users get early access and a direct line to shape what MyRONKO becomes.

That’s the goal. We’ll do everything possible to preserve beta user data through general launch. If a migration or reset ever becomes necessary, beta users will be notified in advance with enough time to export. Your data is always exportable on demand.

Email [email protected] with what happened, what you expected, and (if possible) a screenshot. Feedback from beta users drives the roadmap directly.

Running more than one injectable compound in the same timeframe. Example: tirzepatide weekly for appetite and glucose management, NAD+ three times weekly for energy and cellular recovery, glutathione twice weekly for antioxidant support. Single-compound tracking apps handle one of these at a time. A stack needs tools built for the overlap.

People do. Whether you should is a conversation for your prescriber. From a tracking standpoint, overlapping compounds require separate dose logs per compound, injection site rotation that doesn’t double up, BUD tracking per vial, and schedule coordination so dose days don’t collide unintentionally.

FUN FACT: That’s the use case MyRONKO was built for. 😎

The cleanest approach: assign each compound to a body zone, then rotate within that zone. Example: tirzepatide on upper abdomen alternating left and right weekly, NAD+ on lower abdomen rotating left/center/right across dose days, glutathione on thighs alternating sides. This keeps tissue from getting overworked in one spot and prevents lump formation. If a zone gets tender, swap in a backup, but keep the rotation consistent enough to track reactions.

BUD stands for Beyond-Use Date. The date after which a compounded medication shouldn’t be used, set by the compounding pharmacy based on formulation. Typical range: 90 days to 12 months depending on the compound, concentration, and additives like B6 or bacteriostatic water. Expiration is the manufacturer’s date on a commercially produced drug. Brand-name medications carry it. Compounded medications do not. Track BUD for compounded vials. Track expiration for anything commercial. They’re not interchangeable.

Basic formula: Dose (mg) ÷ Concentration (mg/mL) = Volume (mL). Example: a 12 mg tirzepatide dose from an 18 mg/mL vial equals 12 ÷ 18, or 0.67 mL (67 units on a 100-unit insulin syringe). MyRONKO does this math for you once the vial is logged.

Depends on vial volume, concentration, and your dose. Example: a 4 mL vial of 18 mg/mL tirzepatide contains 72 mg. At a 12 mg weekly dose, that’s 6 shots. At 10 mg, that’s a bit over 7. Vial inventory and per-shot math is tracked automatically in the app.

Log each vial when it arrives (volume, concentration, BUD). Log each shot drawn from it. The app tracks remaining mL, remaining doses at your current dosing, and flags low supply before you run dry.

Both are GLP-1 receptor agonists used for weight management and type 2 diabetes. Semaglutide (Ozempic®, Wegovy®, Rybelsus®) acts on the GLP-1 receptor only. Tirzepatide (Mounjaro®, Zepbound®) is a dual agonist, hitting both GLP-1 and GIP receptors. In clinical trials, tirzepatide produced greater average weight loss than semaglutide. Individual response varies. Side effect profiles overlap but aren’t identical.

A version of the drug prepared by a licensed compounding pharmacy rather than the brand-name manufacturer. During FDA-declared shortages, compounding pharmacies can legally produce alternatives. Outside of shortage status, compounding is more restricted. Formulations typically need to be clinically different (different concentration, additive, or route of administration) to be permitted.

Safety depends on the pharmacy. Things worth verifying: state licensure and current inspection status, 503A vs 503B designation (503B is held to higher manufacturing standards), FDA registration searchable in the FDA Drug Establishments database, warning letter history or prior enforcement actions, third-party testing for sterility and potency (often published as Certificates of Analysis). A well-run compounding pharmacy is a legitimate operation. A sketchy one is a health hazard. The difference is research, not marketing.

503A pharmacies compound patient-specific prescriptions based on an individual doctor’s order. They’re regulated by state boards of pharmacy. 503B pharmacies are FDA-registered outsourcing facilities held to current good manufacturing practice (CGMP) standards similar to drug manufacturers. They can produce larger batches and ship broader supply. Many users prefer 503B for longer BUD, more consistent formulations, and federal oversight.

Not naming names. What to look for: state licensure verification in every state they ship to, FDA registration especially for 503B facilities, clean inspection and warning letter history, published Certificates of Analysis for sterility and potency, and established telehealth partners that vet their pharmacy side.

It happens. FDA guidance shifts, shortages resolve, business decisions change. When it does: finish any vials you have within BUD, transition to a new source with time to spare (not at zero), don’t stockpile past what you can actually use before BUD hits. Supply planning and BUD countdowns are exactly why MyRONKO exists.